Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3

References

• Cengel KA, Hahn SM. Photodynamic Therapy. Cancer 2008; 767 - 74; PMID: 18098271
   PubMed Web of Science ®Google Scholar
• Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, et al. Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res 2004; 10:4630 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-04-0359; PMID: 15269134
   PubMed Web of Science ®Google Scholar
• Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006; 12:2517 - 25; http://dx.doi.org/10.1158/1078-0432.CCR-05-1625; PMID: 16638861
   PubMed Web of Science ®Google Scholar
• Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res 2006; 12:5464 - 70; http://dx.doi.org/10.1158/1078-0432.CCR-06-0953; PMID: 17000681
   PubMed Web of Science ®Google Scholar
• Friedberg J, Cengel K. Pleural Malignancies. Semin Radiat Oncol 2009; 20:208 - 14; PMID: 20685584
   PubMed Web of Science ®Google Scholar
• Cengel KA, Glatstein E, Hahn SM. Intraperitoneal photodynamic therapy. Cancer Treat Res 2007; 134:493 - 514; PMID: 17633077
   PubMedGoogle Scholar
• Solban N, Rizvi I, Hasan T. Targeted photodynamic therapy. Lasers Surg Med 2006; 38:522 - 31; http://dx.doi.org/10.1002/lsm.20345; PMID: 16671102
   PubMed Web of Science ®Google Scholar
• Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004; 1704:59 - 86; PMID: 15363861
   PubMed Web of Science ®Google Scholar
• Cengel KA, Hahn SM, Glatstein E. C225 and PDT combination therapy for ovarian cancer: the play’s the thing. J Natl Cancer Inst 2005; 97:1488 - 9; http://dx.doi.org/10.1093/jnci/dji360; PMID: 16234556
   PubMed Web of Science ®Google Scholar
• del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005; 97:1516 - 24; http://dx.doi.org/10.1093/jnci/dji314; PMID: 16234565
   PubMed Web of Science ®Google Scholar
• Fontanini G, De Laurentiis M, Vignati S, Chinè S, Lucchi M, Silvestri V, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4:241 - 9; PMID: 9516978
   PubMed Web of Science ®Google Scholar
• Ahmad N, Kalka K, Mukhtar H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001; 20:2314 - 7; http://dx.doi.org/10.1038/sj.onc.1204313; PMID: 11402326
   PubMed Web of Science ®Google Scholar
• Wong TW, Tracy E, Oseroff AR, Baumann H. Photodynamic therapy mediates immediate loss of cellular responsiveness to cytokines and growth factors. Cancer Res 2003; 63:3812 - 8; PMID: 12839978
   PubMed Web of Science ®Google Scholar
• Liu W, Oseroff AR, Baumann H. Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin-6 cytokine responsiveness in epithelial cells. Cancer Res 2004; 64:6579 - 87; http://dx.doi.org/10.1158/0008-5472.CAN-04-1580; PMID: 15374971
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129 - 39; http://dx.doi.org/10.1056/NEJMoa040938; PMID: 15118073
   PubMed Web of Science ®Google Scholar
• Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006; 12:7117 - 25; http://dx.doi.org/10.1158/1078-0432.CCR-06-0760; PMID: 17145836
   PubMed Web of Science ®Google Scholar
• Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005; 65:9455 - 62; http://dx.doi.org/10.1158/0008-5472.CAN-05-1058; PMID: 16230409
   PubMed Web of Science ®Google Scholar
• Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (“Iressa”). Br J Cancer 2002; 86:456 - 62; http://dx.doi.org/10.1038/sj.bjc.6600058; PMID: 11875715
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28:3801 - 13; http://dx.doi.org/10.1038/onc.2009.234; PMID: 19684613
   PubMed Web of Science ®Google Scholar
• Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res 2009; 15:6484 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-2813; PMID: 19861462
   PubMed Web of Science ®Google Scholar
• Henderson BW, Daroqui C, Tracy E, Vaughan LA, Loewen GM, Cooper MT, et al. Cross-linking of signal transducer and activator of transcription 3--a molecular marker for the photodynamic reaction in cells and tumors. Clin Cancer Res 2007; 13:3156 - 63; http://dx.doi.org/10.1158/1078-0432.CCR-06-2950; PMID: 17545518
   PubMed Web of Science ®Google Scholar
• Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007; 13:2463 - 70; http://dx.doi.org/10.1158/1078-0432.CCR-06-1599; PMID: 17438106
   PubMed Web of Science ®Google Scholar
• Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007; 9:341 - 8; http://dx.doi.org/10.1593/neo.06823; PMID: 17460778
   PubMed Web of Science ®Google Scholar
• Godbout JP, Cengel KA, Cheng SL, Minshall C, Kelley KW, Freund GG. Insulin activates caspase-3 by a phosphatidylinositol 3′-kinase-dependent pathway. Cell Signal 1999; 11:15 - 23; http://dx.doi.org/10.1016/S0898-6568(98)00024-2; PMID: 10206340
   PubMed Web of Science ®Google Scholar
• Agostinis P, Donella-Deana A, Cuveele J, Vandenbogaerde A, Sarno S, Merlevede W, et al. A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives. Biochem Biophys Res Commun 1996; 220:613 - 7; http://dx.doi.org/10.1006/bbrc.1996.0451; PMID: 8607812
   PubMed Web of Science ®Google Scholar
• Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67:11012 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-07-2686; PMID: 18006847
   PubMed Web of Science ®Google Scholar
• Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005; 65:8433 - 41; http://dx.doi.org/10.1158/0008-5472.CAN-05-0158; PMID: 16166322
   PubMed Web of Science ®Google Scholar
• Cengel KA, Kason RE, Freund GG. Phosphatidylinositol 3′-kinase associates with an insulin receptor substrate-1 serine kinase distinct from its intrinsic serine kinase. Biochem J 1998; 335:397 - 404; PMID: 9761740
   PubMed Web of Science ®Google Scholar
• Cengel KA, Freund GG. JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation. J Biol Chem 1999; 274:27969 - 74; http://dx.doi.org/10.1074/jbc.274.39.27969; PMID: 10488146
   PubMed Web of Science ®Google Scholar
• Horan AD, Giandomenico AR, Koch CJ. Effect of oxygen on radiation-induced DNA damage in isolated nuclei. Radiat Res 1999; 152:144 - 53; http://dx.doi.org/10.2307/3580087; PMID: 10409323
   PubMed Web of Science ®Google Scholar
• Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 2005; 4:197 - 206; http://dx.doi.org/10.4161/cbt.4.2.1441; PMID: 15753652
   PubMed Web of Science ®Google Scholar
• Harris EE, Hwang WT, Lee EA, Cengel KA, Feldman MD, Demichele A, et al. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Breast J 2006; 12:431 - 6; http://dx.doi.org/10.1111/j.1075-122X.2006.00297.x; PMID: 16958961
   PubMed Web of Science ®Google Scholar
• Cengel KA, Deutsch E, Stephens TC, Voong KR, Kao GD, Bernhard EJ. Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines. Cancer Biol Ther 2006; 5:1206 - 10; http://dx.doi.org/10.4161/cbt.5.9.3172; PMID: 16969121
   PubMed Web of Science ®Google Scholar